Nuvigil Labeling Will Likely Include Safety Information From Sparlon Clinical Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Cephalon’s follow-on product gets “approvable” letter as FDA considers common labeling for Provigil, Sparlon and Nuvigil.
You may also be interested in...
Nuvigil Draft Label Warning Includes Both Modafinil And Its Follow-On
Cephalon’s follow-on to the sleep disorder agent Provigil could be on the market by summer, despite “approvable” letter announced March 30.
Nuvigil Draft Label Warning Includes Both Modafinil And Its Follow-On
Cephalon’s follow-on to the sleep disorder agent Provigil could be on the market by summer, despite “approvable” letter announced March 30.
Sparlon User Fee Date Extended To August
FDA has extended the user fee date for Cephalon's attention deficit/hyperactivity disorder treatment Sparlon (modafinil) to Aug. 22, the company said April 24